cognitive cybersecurity intelligence
Athira Pharma’s stock price fell 81% as its lead fosgonimeton treatment for Alzheimer’s disease failed its phase II/III LIFT-AD clinical trial. The drug did not meet the trial’s primary or key secondary endpoints. However, chief medical officer Javier San Martin said Athira planned to continue developing fosgonimeton, citing preliminary results from various subgroups.
Subscribe to HEAL Security Dispatch for the latest healthcare cybersecurity news and analysis.
SECURITY AFFAIRS MALWARE NEWSLETTER ROUND 80 Security Affairs
Programs that combine personal outreach with smart use of technology close more care gaps, improve quality measures, build member loyalty and improve retention. The post
SAN FRANCISCO—No sooner did the J.P. Morgan 44th Annual Healthcare Conference kick off when Sarepta Therapeutics (SRPT) saw its stock skid 11% after the company
The Japan Times reports: Japan’s nuclear regulator has reported the loss of a work-issued smartphone containing highly sensitive contact information after an employee misplaced the
